{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:33:43Z","timestamp":1791999223155,"version":"4.4.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compared with platinum-based chemotherapy, the combination of enfortumab vedotin and pembrolizumab (EV + Pembro) achieves higher durable response rates and improves survival outcomes in patients with locally advanced or metastatic urothelial carcinoma. As the first regimen pairing an immune checkpoint inhibitor with an antibody-drug conjugate, it offers a novel, effective option. Yet evidence has largely been derived from clinical trials, and robust, comprehensive real-world characterization of adverse drug events (ADEs) remains limited. It is therefore essential to examine recent real-world data to delineate the safety profile of EV + Pembro with greater precision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted disproportionality analyses of ADE reports related to EV + Pembro from the FDA Adverse Event Reporting System (FAERS) and the WHO VigiBase. Signal detection algorithms, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN), were used to identify significant safety signals. Additionally, the time to onset of ADEs was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 892 reports from VigiBase and 1,698 reports from FAERS were analyzed across 25 system organ classes. Several previously unlisted ADEs in the product labeling were identified, such as dehydration, cholestasis, ileus, and tumor lysis syndrome. Subgroup analysis revealed that male patients were more prone to dehydration and renal impairment, while female patients were more likely to experience skin discoloration and alopecia. The median onset time for ADEs was 18 days, with males experiencing ADEs significantly earlier than females. Immune system disorders had the shortest median onset time, while surgical and medical procedures had the longest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world analysis confirms known adverse reactions and identifies new safety signals for EV + Pembro. It also highlights differential risk profiles across subgroups, providing valuable insights for clinical practice. Further research is needed to validate these findings and refine patient management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1759135","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:46Z","timestamp":1781760646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS"],"prefix":"10.3389","volume":"17","author":[{"given":"Zuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Fourth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuowen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runjuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiying","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Medicine, Shanghai University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefen","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Fourth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"School of Pharmacy, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1195","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"Chalasani","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"Esmo clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2473695","article-title":"Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma","volume":"34","author":"Santoni","year":"2025","journal-title":"Expert Opin Invest Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett"},{"key":"B6","unstructured":"Padcev (Enfortumab Vedotin-Ejfv) for Injection\n          \n          \n          \n          2023"},{"key":"B7","unstructured":"Keytruda (Pembrolizumab) Injection\n          \n          \n          \n          2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/jco.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-1393","article-title":"Fda approval summary: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102453","DOI":"10.1016\/j.clgc.2025.102453","article-title":"Real-world outcomes of enfortumab vedotin and pembrolizumab in advanced urothelial carcinoma: A multicenter retrospective analysis","volume":"23","author":"Jain","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B12","unstructured":"Fda Adverse Event Reporting System (Faers) Database"},{"key":"B13","unstructured":"Vigibase Search Services"},{"key":"B14","unstructured":"What is a Serious Adverse Event"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2490271","article-title":"A real-world disproportionality analysis of cidofovir from the Fda adverse event reporting system (Faers) database","volume":"24","author":"Liu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the Us Fda's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the Faers database","volume":"362","author":"Gu","year":"2024","journal-title":"J Affect Disord"},{"key":"B20","unstructured":"Common Terminology Criteria for Adverse Events (Ctcae), Version 6.0"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024","article-title":"Bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B22","unstructured":"Eau Guidelines on Mibc. Introduction - Uroweb [Internet]. Uroweb - Eur. Assoc. Urol. [Cited 2025 October 30]"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00765-8","article-title":"Patient preferences in the treatment of genitourinary cancers","volume":"20","author":"Benjamin","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1186\/s12885-024-13075-y","article-title":"Use of inpatient systemic chemotherapy and\/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: Findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy","volume":"24","author":"Kearney","year":"2024","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: Redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190850","article-title":"An updated review of gastrointestinal toxicity induced by Pd-1 inhibitors: From mechanisms to management","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.02.009","article-title":"Immune-related cutaneous adverse events due to checkpoint inhibitors","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052502","article-title":"Association between immune checkpoint inhibitors and atherosclerotic cardiovascular disease risk: Another brick in the wall","volume":"25","author":"Piras","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","article-title":"Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies","volume":"17","author":"Kaur","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13017-019-0240-7","article-title":"Bowel obstruction: A narrative review for all physicians","volume":"14","author":"Catena","year":"2019","journal-title":"World J Emerg Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-025-00877-4","article-title":"Gastrointestinal toxicity of antibody-drug conjugates: A pharmacovigilance study using the Faers database","volume":"26","author":"Shi","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.13239","article-title":"Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions","volume":"318","author":"Dougan","year":"2023","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.70069","article-title":"Successful management of tumor lysis syndrome following enfortumab vedotin plus pembrolizumab therapy in metastatic urothelial carcinoma: A case report","volume":"8","author":"Takemori","year":"2025","journal-title":"IJU Case Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13293-021-00373-4","article-title":"Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history","volume":"12","author":"Loutradis","year":"2021","journal-title":"Biol Sex Differ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5616","article-title":"Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study","volume":"12","author":"Chan","year":"2023","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.885","article-title":"Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study","volume":"87","author":"Bui","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jdin.2023.06.014","article-title":"Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome","volume":"13","author":"Wasuwanich","year":"2023","journal-title":"JAAD Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: Are we all equal","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4039","article-title":"Cancer-related hair loss: A selective review of the alopecia research literature","volume":"26","author":"Dua","year":"2017","journal-title":"Psychooncology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50393","article-title":"Sex is a major determinant of Cyp3a4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173071","article-title":"Mechanistic insights into the successful development of combination therapy of enfortumab vedotin and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer","volume":"16","author":"Taylor","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1759135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:30:49Z","timestamp":1781760649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1759135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1759135"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1759135","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1759135"}}